158 related articles for article (PubMed ID: 19048780)
21. Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity.
Eap CB; Buclin T; Cucchia G; Zullino D; Hustert E; Bleiber G; Golay KP; Aubert AC; Baumann P; Telenti A; Kerb R
Eur J Clin Pharmacol; 2004 Jun; 60(4):237-46. PubMed ID: 15114429
[TBL] [Abstract][Full Text] [Related]
22. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms.
Perloff MD; von Moltke LL; Court MH; Kotegawa T; Shader RI; Greenblatt DJ
J Pharmacol Exp Ther; 2000 Feb; 292(2):618-28. PubMed ID: 10640299
[TBL] [Abstract][Full Text] [Related]
23. Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolam.
Katzenmaier S; Markert C; Mikus G
Eur J Clin Pharmacol; 2010 Nov; 66(11):1137-41. PubMed ID: 20680253
[TBL] [Abstract][Full Text] [Related]
24. Effects of short-term and long-term pretreatment of Schisandra lignans on regulating hepatic and intestinal CYP3A in rats.
Lai L; Hao H; Wang Q; Zheng C; Zhou F; Liu Y; Wang Y; Yu G; Kang A; Peng Y; Wang G; Chen X
Drug Metab Dispos; 2009 Dec; 37(12):2399-407. PubMed ID: 19741040
[TBL] [Abstract][Full Text] [Related]
25. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
[TBL] [Abstract][Full Text] [Related]
26. Inhibitory Effect of Oxethazaine on Midazolam Metabolism in Rats.
Namba H; Nishimura Y; Kurata N; Iwase M; Hirai T; Kiuchi Y
Biol Pharm Bull; 2017; 40(9):1361-1365. PubMed ID: 28867721
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of partial area under the concentration time curve to estimate midazolam apparent oral clearance for cytochrome P450 3A phenotyping.
Tai W; Gong SL; Tsunoda SM; Greenberg HE; Gorski JC; Penzak SR; Stoch SA; Ma JD
Drug Metabol Drug Interact; 2013; 28(4):217-23. PubMed ID: 24114901
[TBL] [Abstract][Full Text] [Related]
28. Sex-dependent differences in cytochrome P450 3A activity as assessed by midazolam disposition in humans: a meta-analysis.
Hu ZY; Zhao YS
Drug Metab Dispos; 2010 May; 38(5):817-23. PubMed ID: 20164111
[TBL] [Abstract][Full Text] [Related]
29. Glycyrrhizin accelerates the metabolism of triptolide through induction of CYP3A in rats.
Tai T; Huang X; Su Y; Ji J; Su Y; Jiang Z; Zhang L
J Ethnopharmacol; 2014 Mar; 152(2):358-63. PubMed ID: 24486211
[TBL] [Abstract][Full Text] [Related]
30. Midazolam and cortisol metabolism before and after CYP3A induction in humans.
Eeckhoudt SL; Desager JP; Robert AR; Leclercq I; Verbeeck RK; Horsmans Y
Int J Clin Pharmacol Ther; 2001 Jul; 39(7):293-9. PubMed ID: 11471773
[TBL] [Abstract][Full Text] [Related]
31. Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects.
Kasichayanula S; Boulton DW; Luo WL; Rodrigues AD; Yang Z; Goodenough A; Lee M; Jemal M; LaCreta F
Br J Clin Pharmacol; 2014 Nov; 78(5):1122-34. PubMed ID: 24837659
[TBL] [Abstract][Full Text] [Related]
32. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
[TBL] [Abstract][Full Text] [Related]
33. Limited sampling models for oral midazolam: midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomarker of CYP3A activity.
Lee LS; Bertino JS; Nafziger AN
J Clin Pharmacol; 2006 Feb; 46(2):229-34. PubMed ID: 16432275
[TBL] [Abstract][Full Text] [Related]
34. Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity.
Fuchs I; Hafner-Blumenstiel V; Markert C; Burhenne J; Weiss J; Haefeli WE; Mikus G
Eur J Clin Pharmacol; 2013 Mar; 69(3):507-13. PubMed ID: 22968811
[TBL] [Abstract][Full Text] [Related]
35. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
36. Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam.
Chen M; Nafziger AN; Bertino JS
Drug Metab Dispos; 2006 Dec; 34(12):2079-82. PubMed ID: 16997909
[TBL] [Abstract][Full Text] [Related]
37. Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam.
Granvil CP; Yu AM; Elizondo G; Akiyama TE; Cheung C; Feigenbaum L; Krausz KW; Gonzalez FJ
Drug Metab Dispos; 2003 May; 31(5):548-58. PubMed ID: 12695342
[TBL] [Abstract][Full Text] [Related]
38. Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole.
Han B; Mao J; Chien JY; Hall SD
Drug Metab Dispos; 2013 Jul; 41(7):1329-38. PubMed ID: 23584886
[TBL] [Abstract][Full Text] [Related]
39. Assessment of oral midazolam limited sampling strategies to predict area under the concentration time curve (AUC) during cytochrome P450 (CYP) 3A baseline, inhibition and induction or activation.
Ma JD; Nguyen ET; Tsunoda SM; Greenberg HE; Gorski JC; Penzak SR; Lee LS
Int J Clin Pharmacol Ther; 2010 Dec; 48(12):847-53. PubMed ID: 21084040
[TBL] [Abstract][Full Text] [Related]
40. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
Chaobal HN; Kharasch ED
Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]